US Postarrival Evaluation of Immigrant and Refugee Children with Latent Tuberculosis Infection Diagnosed Overseas, 2007-2019

Overview

Journal J Pediatr

Specialty Pediatrics

Date 2022 Feb 5

PMID 35120982

Authors

Zanju Wang

Drew L Posey

Richard J Brostrom

Sapna Bamrah Morris

Nina Marano

Christina R Phares

Affiliations

Soon will be listed here.

Abstract

Objective: To assess outcomes from the US postarrival evaluation of newly arrived immigrant and refugee children aged 2-14 years who were diagnosed with latent tuberculosis infection (LTBI) during a required overseas medical examination.

Study Design: We compared overseas and US interferon-γ release assay (IGRA)/tuberculin skin test (TST) results and LTBI diagnosis; assessed postarrival LTBI treatment initiation and completion; and evaluated the impact of switching from TST to IGRA to detect Mycobacterium tuberculosis infection overseas.

Results: In total, 73 014 children were diagnosed with LTBI overseas and arrived in the US during 2007-2019. In the US, 45 939 (62.9%) completed, and 1985 (2.7%) initiated but did not complete a postarrival evaluation. Among these 47 924 children, 30 360 (63.4%) were retested for M tuberculosis infection. For 17 996 children with a positive overseas TST, 73.8% were negative when retested by IGRA. For 1051 children with a positive overseas IGRA, 58.0% were negative when retested by IGRA. Overall, among children who completed a postarrival evaluation, 18 544 (40.4%) were evaluated as having no evidence of TB infection, and 25 919 (56.4%) had their overseas LTBI diagnosis confirmed. Among the latter, 17 229 (66.5%) initiated and 9185 (35.4%) completed LTBI treatment.

Conclusions: Requiring IGRA testing overseas could more effectively identify children who will benefit from LTBI treatment. However, IGRA reversions may occur, highlighting the need for individualized assessment for risk of infection, progression, and poor outcome when making diagnostic and treatment decisions. Strategies are needed to increase the proportions receiving a postarrival evaluation and completing LTBI treatment.

Citing Articles

Overlooked, dismissed, and downplayed: reversion of immunoreactivity.

Dale K, Schwalb A, Coussens A, Gibney K, Abboud A, Watts K Eur Respir Rev. 2024; 33(173).

PMID: 39048129 PMC: 11267292. DOI: 10.1183/16000617.0007-2024.

Tuberculosis Disease Among Nonimmigrant Visa Holders Reported to US Quarantine Stations, January 2011-June 2016.

Vonnahme L, Shaw K, Gulati R, Hollberg M, Posey D, Regan J J Immigr Minor Health. 2024; 26(5):823-829.

PMID: 38834868 PMC: 11413147. DOI: 10.1007/s10903-024-01601-w.

Tuberculosis in United States-Bound Follow-to-Join Asylees, 2014-2019.

Liu Y, Posey D, Weinberg M, Phares C Am J Trop Med Hyg. 2024; 110(5):999-1005.

PMID: 38531107 PMC: 11066364. DOI: 10.4269/ajtmh.23-0233.

Non-Coding RNAs in Tuberculosis Epidemiology: Platforms and Approaches for Investigating the Genome's Dark Matter.

Almatroudi A Int J Mol Sci. 2022; 23(8).

PMID: 35457250 PMC: 9024992. DOI: 10.3390/ijms23084430.

References

Lowenthal P, Barry P, Flood J . High Discordance Between Pre-US and Post-US Entry Tuberculosis Test Results Among Immigrant Children: Is it Time to Adopt Interferon Gamma Release Assay for Preentry Tuberculosis Screening?. Pediatr Infect Dis J. 2015; 35(3):231-6. DOI: 10.1097/INF.0000000000000986. View

Alsdurf H, Hill P, Matteelli A, Getahun H, Menzies D . The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(11):1269-1278. DOI: 10.1016/S1473-3099(16)30216-X. View

Howley M, Painter J, Katz D, Graviss E, Reves R, Beavers S . Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection. Pediatr Infect Dis J. 2014; 34(1):35-9. PMC: 5136477. DOI: 10.1097/INF.0000000000000494. View

. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This.... Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1376-95. DOI: 10.1164/ajrccm.161.4.16141. View

Lighter J, Rigaud M, Eduardo R, Peng C, Pollack H . Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics. 2009; 123(1):30-7. DOI: 10.1542/peds.2007-3618. View

Ho C, Feng P, Narita M, Stout J, Chen M, Pascopella L . Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. Lancet Infect Dis. 2021; 22(1):85-96. PMC: 8712384. DOI: 10.1016/S1473-3099(21)00145-6. View

Lalvani A, Pareek M . A 100 year update on diagnosis of tuberculosis infection. Br Med Bull. 2009; 93:69-84. DOI: 10.1093/bmb/ldp039. View

Marais B, Gie R, Schaaf H, Hesseling A, Obihara C, Starke J . The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004; 8(4):392-402. View

Rutherford M, Nataprawira M, Yulita I, Apriani L, Maharani W, van Crevel R . QuantiFERON®-TB Gold In-Tube assay vs. tuberculin skin test in Indonesian children living with a tuberculosis case. Int J Tuberc Lung Dis. 2012; 16(4):496-502. DOI: 10.5588/ijtld.11.0491. View

10.

Ricks P, Cain K, Oeltmann J, Kammerer J, Moonan P . Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005-2009. PLoS One. 2011; 6(11):e27405. PMC: 3226620. DOI: 10.1371/journal.pone.0027405. View

11.

Schwartz N, Price S, Pratt R, Langer A . Tuberculosis - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020; 69(11):286-289. PMC: 7739979. DOI: 10.15585/mmwr.mm6911a3. View

12.

Verhagen L, Maes M, Villalba J, dAlessandro A, Rodriguez L, Espana M . Agreement between QuantiFERON®-TB Gold In-Tube and the tuberculin skin test and predictors of positive test results in Warao Amerindian pediatric tuberculosis contacts. BMC Infect Dis. 2014; 14:383. PMC: 4227090. DOI: 10.1186/1471-2334-14-383. View

13.

Lonnroth K, Migliori G, Abubakar I, DAmbrosio L, de Vries G, Diel R . Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015; 45(4):928-52. PMC: 4391660. DOI: 10.1183/09031936.00214014. View

14.

Hill P, Brookes R, Fox A, Jackson-Sillah D, Jeffries D, Lugos M . Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 2007; 4(6):e192. PMC: 1891317. DOI: 10.1371/journal.pmed.0040192. View

15.

Lee D, Philen R, Wang Z, McSpadden P, Posey D, Ortega L . Disease surveillance among newly arriving refugees and immigrants--Electronic Disease Notification System, United States, 2009. MMWR Surveill Summ. 2013; 62(7):1-20. View

16.

Cowger T, Wortham J, Burton D . Epidemiology of tuberculosis among children and adolescents in the USA, 2007-17: an analysis of national surveillance data. Lancet Public Health. 2019; 4(10):e506-e516. PMC: 8972148. DOI: 10.1016/S2468-2667(19)30134-3. View

17.

Starke J . Interferon-γ release assays for diagnosis of tuberculosis infection and disease in children. Pediatrics. 2014; 134(6):e1763-73. DOI: 10.1542/peds.2014-2983. View

18.

Winston C, Menzies H . Pediatric and adolescent tuberculosis in the United States, 2008-2010. Pediatrics. 2012; 130(6):e1425-32. PMC: 4602373. DOI: 10.1542/peds.2012-1057. View

19.

Yu X, Liu P, Liu G, Zhao L, Hu Y, Wei G . The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect. 2016; 73(6):558-567. DOI: 10.1016/j.jinf.2016.08.020. View

20.

Posey D, Naughton M, Willacy E, Russell M, Olson C, Godwin C . Implementation of new TB screening requirements for U.S.-bound immigrants and refugees - 2007-2014. MMWR Morb Mortal Wkly Rep. 2014; 63(11):234-6. PMC: 4584633. View